Montserrat Ixchel González-Pérez1,2, José Guillermo Mejía-Hurtado1,2, Diana Isabel Pérez-Román1,2, Ivette Buendía-Roldán1,2, Mayra Mejía1,2, Ramcés Falfán-Valencia1,2, Heidegger N Mateos-Toledo1,2, Jorge Rojas-Serrano3,4. 1. From the Interstitial Lung Disease and Rheumatology Unit, and HLA Laboratory, and Research Direction, Instituto Nacional de Enfermedades Respiratorias; Programa de Maestría y Doctorado en Ciencias Médicas, Facultad de Medicina, Universidad Nacional Autónoma de México, México City, México. 2. M.I. González-Pérez, MD, Interstitial Lung Disease and Rheumatology Unit, Instituto Nacional de Enfermedades Respiratorias; J.G. Mejía-Hurtado, MD, Interstitial Lung Disease and Rheumatology Unit, Instituto Nacional de Enfermedades Respiratorias; D.I. Pérez-Román, MD, Interstitial Lung Disease and Rheumatology Unit, Instituto Nacional de Enfermedades Respiratorias; I. Buendía-Roldán, MD, PhD, Research Direction, Instituto Nacional de Enfermedades Respiratorias; M. Mejía, MD, Interstitial Lung Disease and Rheumatology Unit, Instituto Nacional de Enfermedades Respiratorias; R. Falfán-Valencia, PhD, HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias; H.N. Mateos-Toledo, MD, Professor, Programa de Maestría y Doctorado en Ciencias Médicas, Facultad de Medicina, Universidad Nacional Autónoma de México; J. Rojas-Serrano, MD, PhD, Interstitial Lung Disease and Rheumatology Unit, Instituto Nacional de Enfermedades Respiratorias, and Professor, Programa de Maestría y Doctorado en Ciencias Médicas, Facultad de Medicina, Universidad Nacional Autónoma de México. 3. From the Interstitial Lung Disease and Rheumatology Unit, and HLA Laboratory, and Research Direction, Instituto Nacional de Enfermedades Respiratorias; Programa de Maestría y Doctorado en Ciencias Médicas, Facultad de Medicina, Universidad Nacional Autónoma de México, México City, México. jrojas@iner.gob.mx. 4. M.I. González-Pérez, MD, Interstitial Lung Disease and Rheumatology Unit, Instituto Nacional de Enfermedades Respiratorias; J.G. Mejía-Hurtado, MD, Interstitial Lung Disease and Rheumatology Unit, Instituto Nacional de Enfermedades Respiratorias; D.I. Pérez-Román, MD, Interstitial Lung Disease and Rheumatology Unit, Instituto Nacional de Enfermedades Respiratorias; I. Buendía-Roldán, MD, PhD, Research Direction, Instituto Nacional de Enfermedades Respiratorias; M. Mejía, MD, Interstitial Lung Disease and Rheumatology Unit, Instituto Nacional de Enfermedades Respiratorias; R. Falfán-Valencia, PhD, HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias; H.N. Mateos-Toledo, MD, Professor, Programa de Maestría y Doctorado en Ciencias Médicas, Facultad de Medicina, Universidad Nacional Autónoma de México; J. Rojas-Serrano, MD, PhD, Interstitial Lung Disease and Rheumatology Unit, Instituto Nacional de Enfermedades Respiratorias, and Professor, Programa de Maestría y Doctorado en Ciencias Médicas, Facultad de Medicina, Universidad Nacional Autónoma de México. jrojas@iner.gob.mx.
Abstract
OBJECTIVE: To describe the evolution of the pulmonary function in patients with interstitial lung disease (ILD) who are positive for at least 1 of the antisynthetase antibodies (ASAB) after medical treatment, and to compare whether the evolution of pulmonary function is associated with the type of ASAB. METHODS: Patients with ILD and positive for at least 1 of the ASAB (anti-Jo1, anti-PL7, anti-PL12, anti-EJ, or anti-OJ) were included. The clinical evolution, time until death or censoring, and improvement of lung disease were registered. RESULTS: The study included 118 patients. Most of the patients had a high extent of ground glass opacities in high-resolution computed tomography (HRCT) and low extent of fibrosis. In the final evaluation of pulmonary function (median 749.5 days of followup), 67% of the patients had lung disease improvement. The improvement occurred within the first 6 months after initiating medical treatment; thereafter, pulmonary function remained stable in most of the patients. A decrease of the extent of ground glass opacities was demonstrated in HRCT at followup in those patients with pulmonary improvement. No differences were observed in the percentage of patients who achieved improvement between the ASAB groups, or in survival. CONCLUSION: Improvement of pulmonary function was observed in 67% of the patients. Improvement was observed in all ASAB groups and occurred within 6 months after initiating medical treatment.
OBJECTIVE: To describe the evolution of the pulmonary function in patients with interstitial lung disease (ILD) who are positive for at least 1 of the antisynthetase antibodies (ASAB) after medical treatment, and to compare whether the evolution of pulmonary function is associated with the type of ASAB. METHODS:Patients with ILD and positive for at least 1 of the ASAB (anti-Jo1, anti-PL7, anti-PL12, anti-EJ, or anti-OJ) were included. The clinical evolution, time until death or censoring, and improvement of lung disease were registered. RESULTS: The study included 118 patients. Most of the patients had a high extent of ground glass opacities in high-resolution computed tomography (HRCT) and low extent of fibrosis. In the final evaluation of pulmonary function (median 749.5 days of followup), 67% of the patients had lung disease improvement. The improvement occurred within the first 6 months after initiating medical treatment; thereafter, pulmonary function remained stable in most of the patients. A decrease of the extent of ground glass opacities was demonstrated in HRCT at followup in those patients with pulmonary improvement. No differences were observed in the percentage of patients who achieved improvement between the ASAB groups, or in survival. CONCLUSION: Improvement of pulmonary function was observed in 67% of the patients. Improvement was observed in all ASAB groups and occurred within 6 months after initiating medical treatment.
Authors: Shaney L Barratt; Havra H Adamali; Caroline Cotton; Ben Mulhearn; Hina Iftikhar; John David Pauling; Lisa Spencer; Huzaifa I Adamali; Harsha Gunawardena Journal: BMJ Open Respir Res Date: 2021-01
Authors: Matthew Wells; Sughra Alawi; Kyaing Yi Mon Thin; Harsha Gunawardena; Adrian R Brown; Anthony Edey; John D Pauling; Shaney L Barratt; Huzaifa I Adamali Journal: Front Med (Lausanne) Date: 2022-09-14